Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine + Chidamide in Newly Diagnosed PTCL Unfit for Chemotherapy
NCT04480125Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jun 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azacitidine, tucidinostat in peripheral T-cell lymphoma (PTCL), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
azacitidinetucidinostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT04480125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480125.